Key Takeaways CORT's revenues are driven by Korlym, which posted $559.3M in nine-month sales in 2025, up 13.4$800M-$850M and sustained Korlym growth.Corcept filed NDAs for relacorilant in Cushing's and ovarian cancer, with FDA decisions due in 2025 and 2026.Corcept Therapeutics (CORT) has been making meaningful progress with its sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome or endogenous hypercortisolism. Cur ...